pharma r&d market
The pharmaceutical R&D process is undergoing a monumental shift. Two-thirds of all new medicines approved at the FDA now originate from emerging and innovative biotech companies such as Reglagene. Pharmaceutical companies have shifted away from reliance on internal R&D to licensing the products for their pipelines from the innovators. Nowhere is this truer than in the competitive oncology market. Cancer will soon pass heart disease as the number one killer on the planet. The oncology therapeutics sector is the largest by product sales, the fastest growing, and will eclipse $200B in annual sales by 2022. Consequently, the licensing market in the oncology sector is white hot. The competition for new oncology medicines that work in new ways is making early licensing more attractive.
Building a Sustainable Business
Reglagene will achieve sustaining revenue through licensing the cancer medicines we create to pharmaceutical industry partners to share downstream costs and product development risk. Because of the fierce competition for exclusive access to game-changing cancer medicines, early licensing is now dominant, with most oncology product licensing deals occurring before a medicine reaches human clinical trials.
The truth is that Reglagene’s gene control technology is unique and has implications for new medicines in oncology and other therapeutic sectors. Several prospective pharmaceutical partners have expressed interest in joint product development programs with Reglagene to apply our technology to pursue gene targets of special interest to the partner. Reglagene is open to and eager for these product development alliances. These will allow Reglagene to scale and de-risk our business while at the same time creating a near-term revenue stream.
Reglagene Is a Portfolio Company of Tucson’s Desert Angels
CONTACT US TO
1703 E Mabel St | Tucson, AZ 85721 | USA